KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Shares Outstanding (Diluted Average): 2013-2025

Historic Shares Outstanding (Diluted Average) for Nektar Therapeutics (NKTR) over the last 10 years, with Sep 2025 value amounting to $18.9 million.

  • Nektar Therapeutics' Shares Outstanding (Diluted Average) rose 35.82% to $18.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.9 million, marking a year-over-year increase of 35.82%. This contributed to the annual value of $205.7 million for FY2024, which is 8.24% up from last year.
  • As of Q3 2025, Nektar Therapeutics' Shares Outstanding (Diluted Average) stood at $18.9 million, which was up 34.49% from $14.1 million recorded in Q2 2025.
  • Nektar Therapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $210.9 million for Q1 2025, and its period low was $13.9 million during Q2 2024.
  • Over the past 3 years, Nektar Therapeutics' median Shares Outstanding (Diluted Average) value was $189.7 million (recorded in 2023), while the average stood at $130.1 million.
  • In the last 5 years, Nektar Therapeutics' Shares Outstanding (Diluted Average) slumped by 92.67% in 2024 and then spiked by 35.82% in 2025.
  • Quarterly analysis of 5 years shows Nektar Therapeutics' Shares Outstanding (Diluted Average) stood at $183.3 million in 2021, then increased by 2.09% to $187.1 million in 2022, then increased by 1.53% to $190.0 million in 2023, then increased by 8.24% to $205.7 million in 2024, then soared by 35.82% to $18.9 million in 2025.
  • Its last three reported values are $18.9 million in Q3 2025, $14.1 million for Q2 2025, and $210.9 million during Q1 2025.